Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Anticipate the outcomes and implications of 2013’s key FDA approval decisions.
Although 2012 witnessed the FDA approve 39 new drugs and biological entities, drugs approved for the treatment of disorders of the central nervous system (CNS) accounted for just two of these successful candidates – Aubagio (teriflunomide) gained approval for multiple sclerosis (MS) and Fycompa (perampanel) for epilepsy.
In 2013 however, we anticipate a far more productive outlook for the CNS sector. Several promising candidates for psychiatric and neurological indications were filed for approval in the US in 2012, with at least six expected to demonstrate significant clinical benefit to win FDA approval over the next 12 months.
Understand our expert view on the likely impact and implications with this free White Paper summary.
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
Looking for more products Product Finder
